Towards a microfluidics platform for the continuous manufacture of organic and inorganic nanoparticles

Desai, Dawood; Guerrero, Yadir; Balachandran, Vaishali; Morton, Alasdair; Lyon, L. Andrew; Larkin, B. K.; Solomon, Deepak E.

doi:10.1016/j.nano.2021.102402

Cited by 15 publications

(12 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nano-formulations can encompass both organic and inorganic materials of synthetic or natural origin for nanomedicine, and hence can be classified as organic or inorganic NPs. 62 Inorganic NPs offer great opportunities in nanomedicine to serve as therapeutic or imaging agents. Commonly used materials for inorganic NPs include metals, metallic oxides, and semiconductors.…”

Section: Microfluidic Synthesis and Separation Strategies For Nano-fo...mentioning

confidence: 99%

Advanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics

Shen,

Gwak,

Han

2024

Analyst

View full text Add to dashboard Cite

show abstract

Section: Microfluidic Synthesis and Separation Strategies For Nano-fo...mentioning

confidence: 99%

Advanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics

Shen,

Gwak,

Han

2024

Analyst

View full text Add to dashboard Cite

show abstract

“…[50] A chaotic micromixer that uses fluidic traps to achieve effective and fast mixing was recently reported. [45] Each mixer is able to operate a TFR = 1.8 l h −1 , and an assembly of five parallel elements was implemented. The platform was proven to produce different types of NPs, both organic (liposomes) and inorganic (metal oxides), with a high level of control on NPs size and composition.…”

Section: Scientific Articles Coveragementioning

confidence: 99%

“…These strategies will eventually become the fastest route towards industrial production of nanocarriers. A lately published work [ 45 ] fits in this R&D path and, in relation to the advantages/disadvantages discussed above, the paper also includes a valuable discussion on some of the technical constraints found when looking for high‐volume production of NPs. In what follows, we examine the works dealing with the enhancement of the microfluidic production rate of NPs for pharmaceutics.…”

Section: Problem Statementmentioning

confidence: 99%

Microfluidic Platforms for the Production of Nanoparticles at Flow Rates Larger Than One Liter Per Hour

Giorello

Nicastro²

2022

Adv Materials Technologies

View full text Add to dashboard Cite

processes, which are essential for the preparation of nanoparticles (NPs) with specific properties. A proof of acceptance of these modern drug formulation processes has been the recent FDA and EMA approval of nucleic acid nanomedicines, first Onpattro [10] and nowadays COVID-19 vaccines, [11] where microfluidics plays an essential R&D role. [12] Regarding massproduction, a limitation of the present microfluidic technology is the relatively low throughput, [13] which is insufficient to meet the good manufacturing practice (GMP) standards of the pharmaceutical industry in terms of final product volumes. Therefore, continuous efforts are being made to upscale the NPs preparation processes, and this is precisely the subject to be analyzed in the present work.Before entering the specific scaling-up problem, it is worth discussing the topic in a wider context. Up to date, nanomedicine has not reached the expected success, which can be explained by the challenges that still remain in formulation, the lack of robust and reproducible manufacturing, the highly demanded characterization methods, and stringent regulatory requirements. [14] Microfluidics has the potential to solve some of these issues and influence the way pharmaceutical R&D is conducted; [15] thus governmental agencies are now backing such initiatives, as mentioned above. It is worth mentioning that microfluidics is not a product but an enabling technology, a versatile tool that has been constantly evolving during the last two decades. [16] For example, early microfluidic components were expensive and time consuming, not only for chips fabrication but also for handling and operation. However, today there is a broad availability of microfabrication, integration, and liquid-handling methods, [17][18][19] which is quickly enlarging the number of users in both industry and academy. There are three expanding sectors producing the major demands on microfluidic technology: i) lab-on-a-chip devices for point-of-care testing, [20] ii) microfluidics-based 3D cell culture systems, such as organ-on-a-chip for precision medicine, [21] and iii) microfluidic platforms for the preparation of smart drug delivery nanosystems. [1][2][3][4] Furthermore, the combination of these applications is generating a number of novel opportunities for the biomedical market, and it is also accelerating the clinical translation of NPs, as envisioned some years ago. [22] Nevertheless, the conversion of these nanomedicine prototypes into marketed products is still limited.The pharmaceutical industry is regarded as rather conservative, a conduct that is well-understood considering the strict The convergence of microfluidics and nanotechnology has demonstrated a synergetic potential for the preparation of advanced pharmaceutics. Nowadays, there is a renewed interest in the subject, boosted by the approval of nucleic acid-loaded lipid-based nanoparticles. Microfluidics enables the physical scenario to achieve well-controlled formulations and plays an essential role in nanocarriers development; ne...

show abstract

“…In particular, there are a variety of NP synthetic conventional methods such as nanoprecipitation, 18 solvent evaporation, 19,20 microemulsions, 21 sol–gel, 22,23 emulsion polymerization, 24 layer-by-layer self-assembly, 25 thin-film hydration, 26 bulk mixing by extrusion, 27 pipette mixing, 28 electrodeposition and thermal decomposition. 29,30 In these methods, the formation of the NPs can be divided into three stages, a) nucleation, b) growth and c) aggregation, which occur concurrently leading to some differences, in terms of physicochemical properties, from batch-to-batch of synthesized NPs. 31 The inability to control the physicochemical properties of each synthetic batch of NPs leads to low reproducibility of both in vitro and consequently in vivo biological tests.…”

Section: Introductionmentioning

confidence: 99%

Design of functional nanoparticles by microfluidic platforms as advanced drug delivery systems for cancer therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

Towards a microfluidics platform for the continuous manufacture of organic and inorganic nanoparticles

Cited by 15 publications

References 52 publications

Advanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics

Advanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics

Microfluidic Platforms for the Production of Nanoparticles at Flow Rates Larger Than One Liter Per Hour

Design of functional nanoparticles by microfluidic platforms as advanced drug delivery systems for cancer therapy

Contact Info

Product

Resources

About